haloperidol and Insulin Resistance studies

Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.

Insulin Resistance: Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.

Research Excerpts

Excerpt	Relevance	Reference
"The aim of this study was to compare serum amino acid patterns in patients on long-term clozapine treatment with long-term conventional antipsychotic treatment, and their relationships to insulin resistance and antipsychotic serum concentrations."	7.81	Higher serum concentrations of tyrosine and glutamate in schizophrenia patients treated with clozapine, compared to in those treated with conventional antipsychotics. ( Hall, K; Lewitt, M; Melkersson, K, 2015)
"The aim of this study was to compare serum amino acid patterns in patients on long-term clozapine treatment with long-term conventional antipsychotic treatment, and their relationships to insulin resistance and antipsychotic serum concentrations."	3.81	Higher serum concentrations of tyrosine and glutamate in schizophrenia patients treated with clozapine, compared to in those treated with conventional antipsychotics. ( Hall, K; Lewitt, M; Melkersson, K, 2015)
" To investigate the possible mechanisms of antipsychotic-induced metabolic effects, we studied the impact of chronic administration of a typical antipsychotic drug (haloperidol) and an atypical antipsychotic (risperidone) to male rats on food intake, body weight, adiposity, and the circulating concentrations of hormones and metabolites that can influence energy homeostasis."	3.73	Distinct endocrine effects of chronic haloperidol or risperidone administration in male rats. ( Dedova, I; Duffy, L; Herzog, H; Karl, T; Lee, NJ; Lin, EJ; Matsumoto, I; O'brien, E; Sainsbury, A; Slack, K, 2006)
"Weight gain was positively correlated with changes in insulin levels, insulin resistance index and triglyceride levels."	2.74	Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-naïve population. ( Amado, JA; Berja, A; Crespo-Facorro, B; Garcia-Unzueta, MT; Martinez-Garcia, O; Mata, I; Pelayo-Teran, JM; Perez-Iglesias, R; Vazquez-Barquero, JL, 2009)
"Haloperidol treatment reduced the voluntary activity and energy expenditure of DR mice and induced insulin resistance in these mice."	1.37	Pharmacological modulation of dopamine receptor D2-mediated transmission alters the metabolic phenotype of diet induced obese and diet resistant C57Bl6 mice. ( de Leeuw van Weenen, JE; Parlevliet, ET; Pijl, H; Romijn, JA; Schröder-van der Elst, JP; van den Berg, SA; Willems van Dijk, K, 2011)

Research

Studies (9)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

BMI

Body Weight

Diastolic Blood Pressure

HDL Cholesterol

Heart Rate

LDL Cholesterol

Oral Glucose Tolerance

Plasma Free Fatty Acid

Plasma Leptin

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (22.22)	29.6817
2010's	7 (77.78)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Calevro, A	1
Cotel, MC	1
Natesan, S	1
Modo, M	1
Vernon, AC	1
Mondelli, V	1
Melkersson, K	1
Lewitt, M	1
Hall, K	1
Perez-Iglesias, R	1
Mata, I	1
Pelayo-Teran, JM	1
Amado, JA	1
Garcia-Unzueta, MT	1
Berja, A	1
Martinez-Garcia, O	1
Vazquez-Barquero, JL	1
Crespo-Facorro, B	1
Boyda, HN	1
Tse, L	1
Procyshyn, RM	1
Wong, D	1
Wu, TK	1
Pang, CC	1
Barr, AM	1
Albaugh, VL	1
Vary, TC	1
Ilkayeva, O	1
Wenner, BR	1
Maresca, KP	1
Joyal, JL	1
Breazeale, S	1
Elich, TD	1
Lang, CH	1
Lynch, CJ	1
Victoriano, M	1
de Beaurepaire, R	1
Naour, N	1
Guerre-Millo, M	1
Quignard-Boulangé, A	1
Huneau, JF	1
Mathé, V	1
Tomé, D	1
Hermier, D	1
de Leeuw van Weenen, JE	2
Auvinen, HE	1
Parlevliet, ET	2
Coomans, CP	1
Schröder-van der Elst, JP	2
Meijer, OC	1
Pijl, H	2
van den Berg, SA	1
Willems van Dijk, K	1
Romijn, JA	1
Lin, EJ	1
Lee, NJ	1
Slack, K	1
Karl, T	1
Duffy, L	1
O'brien, E	1
Matsumoto, I	1
Dedova, I	1
Herzog, H	1
Sainsbury, A	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Double-blind, Placebo-controlled, Crossover Study Examining the Acute Effects of Olanzapine on Plasma Leptin, Glucose Tolerance and Free Fatty Acids in Healthy Volunteers[NCT00741026]		15 participants (Actual)	Interventional	2008-08-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Intervention	kg / m2 (Mean)
Placebo	23.0
Olanzapine	23.0

Intervention	kg (Mean)
Placebo	68.2
Olanzapine	68.9

Intervention	mmHg (Mean)
Placebo	68.3
Olanzapine	69.5

Intervention	mg/dl (Mean)
Placebo	54.2
Olanzapine	48.9

Intervention	beats per minute (Mean)
Placebo	69.9
Olanzapine	67.6

Intervention	mg/dl (Mean)
Placebo	82.7
Olanzapine	81.7

Intervention	min*mg/dl (Mean)
Placebo	2808
Olanzapine	3984

Intervention	mM (Mean)
Placebo	0.38
Olanzapine	0.26

Leptin following placebo or olanzapine treatment (NCT00741026)
Timeframe: 3 Days

Article	Year
Effects of chronic antipsychotic drug exposure on the expression of Translocator Protein and inflammatory markers in rat adipose tissue. Psychoneuroendocrinology, 2018, Volume: 95 Topics: Adipose Tissue; Adiposity; Animals; Antigens, Differentiation; Antipsychotic Agents; Biomarkers; Car	2018
Higher serum concentrations of tyrosine and glutamate in schizophrenia patients treated with clozapine, compared to in those treated with conventional antipsychotics. Neuro endocrinology letters, 2015, Volume: 36, Issue:5 Topics: Adult; Amino Acids; Antipsychotic Agents; Chromatography, Ion Exchange; Clopenthixol; Clozapine; Coh	2015
A parametric study of the acute effects of antipsychotic drugs on glucose sensitivity in an animal model. Progress in neuro-psychopharmacology & biological psychiatry, 2010, Aug-16, Volume: 34, Issue:6 Topics: Analysis of Variance; Animals; Antipsychotic Agents; Blood Glucose; Clozapine; Dose-Response Relatio	2010
Atypical antipsychotics rapidly and inappropriately switch peripheral fuel utilization to lipids, impairing metabolic flexibility in rodents. Schizophrenia bulletin, 2012, Volume: 38, Issue:1 Topics: Animals; Antipsychotic Agents; Benzodiazepines; Carnitine; Clozapine; Energy Metabolism; Fatty Acids	2012
Olanzapine-induced accumulation of adipose tissue is associated with an inflammatory state. Brain research, 2010, Sep-02, Volume: 1350 Topics: Adipose Tissue; Analysis of Variance; Animals; Antipsychotic Agents; Benzodiazepines; Cytokines; Glu	2010
Blocking dopamine D2 receptors by haloperidol curtails the beneficial impact of calorie restriction on the metabolic phenotype of high-fat diet induced obese mice. Journal of neuroendocrinology, 2011, Volume: 23, Issue:2 Topics: Animals; Body Weight; Caloric Restriction; Dietary Fats; Dopamine Antagonists; Dopamine D2 Receptor	2011
Pharmacological modulation of dopamine receptor D2-mediated transmission alters the metabolic phenotype of diet induced obese and diet resistant C57Bl6 mice. Experimental diabetes research, 2011, Volume: 2011 Topics: Animals; Behavior, Animal; Body Weight; Bromocriptine; Dietary Fats; Dopamine Agonists; Dopamine Ant	2011
Distinct endocrine effects of chronic haloperidol or risperidone administration in male rats. Neuropharmacology, 2006, Volume: 51, Issue:7-8 Topics: Adipose Tissue; Animals; Antipsychotic Agents; Appetite; Body Weight; Corticosterone; Diabetes Melli	2006

haloperidol and Insulin Resistance